Intravenous Thrombolysis is Effective in Young Adults: Results from the Baden-Wuerttemberg Stroke Registry

Background The efficacy of intravenous thrombolysis (IVT) is sufficiently proven in ischemic stroke patients of middle and older age by means of randomized controlled trials and large observational studies. However, data in young stroke patients ≤50 years are still scarce. In this study, we aimed to evaluate the effectiveness and safety of IVT in young adults aged 18–50 years. Data from a consecutive and prospective stroke registry was analyzed that covers a federal state with 10.8 million inhabitants in southwest Germany. Methods Our analysis comprises 51,735 ischemic stroke patients aged 18–80 years and hospitalized from January 2008 to December 2012. Of these, 4,140 (8%) were aged 18–50 years and 7,529 (15%) underwent IVT. Data on 8,439 patients (16% of the study population) were missing for National Institutes of Health stroke severity score at admission and/or modified Rankin Scale (mRS) at discharge and were excluded from outcome analysis. In sensitivity analysis, patients with incomplete data were also examined. Binary logistic regression models were used adjusted for patient, hospital, and procedural parameters and stratified by age group (18–50 and 51–80 years, subgroup analyses 18–30, 31–40, and 41–50 years) to assess the relationship between IVT and mRS at discharge. Results IVT appears equally effective in young adults 18–50 years (adjusted odds ratio 1.40, 95% confidence interval 1.12–1.75; p = 0.003), compared to patients 51–80 years of age (1.33, 1.23–1.43; p < 0.001). Age-stratified analyses suggest an inverse relation of age and effectiveness, which appears to be highest in very young patients 18–30 years of age (2.78, 1.10–7.05; p = 0.03). Discussion Ischemic stroke etiology, vascular dynamics, and recovery in young patients differ from those of middle and older age. The evidence from routine hospital care in Germany indicates that IVT in young stroke patients appears to be at least equally effective as in the elderly.

[1]  W. Hacke,et al.  Intravenous thrombolysis for acute ischaemic stroke in the elderly: data from the Baden‐Wuerttemberg stroke registry , 2016, European journal of neurology.

[2]  Mahboubeh Parsaeian,et al.  Tobacco Smoking Status and the Contribution to Burden of Diseases in Iran, 1990-2010: findings from the Global Burden of Disease Study 2010. , 2015, Archives of Iranian medicine.

[3]  D. Prefasi,et al.  Intravenous thrombolysis in stroke patients under 55 years of age: is there a different effect according to etiology and severity? , 2014, Journal of Thrombosis and Thrombolysis.

[4]  V. Feigin,et al.  Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010 , 2014, The Lancet.

[5]  M. Elkind,et al.  Recognition and management of stroke in young adults and adolescents , 2013, Neurology.

[6]  W. Hacke,et al.  A Consecutive and Prospective Stroke Database Covers the State of Baden-Wuerttemberg with 10.8 Million Inhabitants in Germany , 2013, Neuroepidemiology.

[7]  P. Bhattacharya,et al.  Thrombolysis and outcome of young stroke patients over the last decade: insights from the Nationwide Inpatient Sample. , 2013, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[8]  M. Wintermark,et al.  Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.

[9]  C. Kessler,et al.  Lifestyle Risk Factors for Ischemic Stroke and Transient Ischemic Attack in Young Adults in the Stroke in Young Fabry Patients Study , 2013, Stroke.

[10]  Peter Emiley.  Intravenous Thrombolysis in Young Stroke Patients: Results from the SITS-ISTR , 2012 .

[11]  Geoff Cohen,et al.  The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial , 2012, The Lancet.

[12]  M. Kaste,et al.  Intravenous thrombolysis in young stroke patients , 2012, Neurology.

[13]  Mary G. George,et al.  Trends in stroke hospitalizations and associated risk factors among children and young adults, 1995–2008 , 2011, Annals of neurology.

[14]  F. Veith,et al.  Letter by Paraskevas et al regarding article, "Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/american Stroke Association". , 2011, Stroke.

[15]  J. Ferro,et al.  Aetiological diagnosis of ischaemic stroke in young adults , 2010, The Lancet Neurology.

[16]  B. Norrving,et al.  Trends in Baseline Patient Characteristics during the Years 1995–2008: Observations from Riks-Stroke, the Swedish Stroke Register , 2010, Cerebrovascular Diseases.

[17]  J. Saver,et al.  Day-90 Acute Ischemic Stroke Outcomes Can Be Derived from Early Functional Activity Level , 2009, Cerebrovascular Diseases.

[18]  J. Geddes,et al.  What is a randomised controlled trial? , 2009, Epidemiologia e Psichiatria Sociale.

[19]  M. Kaste,et al.  Thrombolysis in Young Adults With Ischemic Stroke , 2009, Stroke.

[20]  A. Nordlund,et al.  Increasing Stroke Incidence in Sweden Between 1989 and 2000 Among Persons Aged 30 to 65 Years: Evidence From the Swedish Hospital Discharge Register , 2004, Stroke.

[21]  L. Schwamm,et al.  Ischemic stroke and transient ischemic attack in young adults: risk factors, diagnostic yield, neuroimaging, and thrombolysis. , 2013, JAMA neurology.

[22]  A. Sergeant.  Thrombolysis in very elderly people: controlled comparison of SITS international stroke thrombolysis registry and virtual international stroke trials archive , 2013 .